Antiviral therapy for influenza: A clinical and economic comparative review

Drugs

Volumn 64, Issue 18, 2004, Pages 2031-2046

  Schmidt, Alexander C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; INFLUENZA VACCINE; OSELTAMIVIR; PARACETAMOL; PLACEBO; PSYCHOTROPIC AGENT; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ANXIETY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GERMANY; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INSOMNIA; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; NAUSEA; NEUROTOXICITY; PRESCHOOL CHILD; REVIEW; SCHOOL CHILD; SIDE EFFECT; UNITED KINGDOM; VIRUS REPLICATION; VOMITING; WHEEZING;

ANTIVIRAL AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; HUMANS; INFLUENZA, HUMAN; PRACTICE GUIDELINES;

INFLUENZA A VIRUS; INFLUENZA VIRUS; INFLUENZAVIRUS B; RNA VIRUSES;

EID: 4644258940     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464180-00003     Document Type: Review

References (66)

1. WHO. Influenza: report to the WHO Executive Board, 2002 Nov 26. Report no.: EB 111/10 [online]. Available from URL: http://www.who.int/gb/ebwha/ pdf_files/EB111/eeb1111r2.pdf [Accessed 2003 Nov 11]
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289 (2): 179-86
3. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002; 15 (2): 295-323
4. Clements ML, Makhene MK, Karron RA, et al. Effective immunization with live attenuated influenza A virus can be achieved in early infancy: Pediatric Care Center. J Infect Dis 1996; 173(1): 44-51
5. Evans MR, Watson PA. Why do older people not get immunised against influenza? A community survey. Vaccine 2003; 21 (19-20): 2421-7
6. Hayden FG. Perspectives on antiviral use during pandemic influenza. Philos Trans R Soc Lond B Biol Sci 2001; 356 (1416): 1877-84
7. Bridges CB, Harper SA, Fukuda K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52 (RR-8): 1-34
8. Lin YP, Shaw M, Gregory V, et al. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci USA 2000; 97 (17): 9654-8
9. Cram P, Blitz SG, Monto A, et al. Influenza: cost of illness and considerations in the economic evaluation of new and emerging therapies. Pharmacoeconomics 2001; 19 (3): 223-30.
10. Simonsen L, Clarke MJ, Williamson GD, et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997; 87 (12): 1944-50.
11. Simonsen L, Fukuda K, Schonberger LB, et al. The impact of influenza epidemics on hospitalizations. J Infect Dis 2000; 181 (3): 831-7
12. Neuzil KM, Reed GW, Mitchel Jr EF, et al. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281 (10): 901-7
13. Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza. London: National Institute for Clinical Excellence, 2003 Feb. Report no.: 58 [online]. Available from URL: http://www.nice.org.uk/ Docref.asp?d=5806 [Accessed 2003 Sep 9]
14. Boivin G, Hardy I, Tellier G, et al. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 2000; 31 (5): 1166-9
15. Govaert TM, Dinant GJ, Aretz K, et al. The predictive value of influenza symptomatology in elderly people. Fam Pract 1998; 15 (1): 16-22
16. Hay AJ, Wolstenholme AJ, Skehel JJ, et al. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4 (11): 3021-4
17. Wang C, Takeuchi K, Pinto LH, et al. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993; 67 (9): 5585-94
18. Sidwell RW, Smee DF. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin Investig Drugs 2002; 11 (6): 859-69
19. Belshe RB, Burk B, Newman F, et al. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989; 159 (3): 430-5
20. Hayden FG. Antiviral agents. In: Hardman JG, Limbird LE, Goodman Gilman A, editor. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: Mc-Graw Hill, 2001: 1313-48
21. Dunn CJ, Goa KL. Zanamivir: a review of its use in influenza. Drugs 1999; 58 (4): 761-84
22. McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs 2001; 61 (2): 263-83
23. Wingfield WL, Pollack D, Grunert RR. Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 1969; 281 (11): 579-84
24. Van Voris LP, Betts RF, Hayden FG, et al. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 1981; 245(11): 1128-31
25. Aoki FY, Sitar DS. Amantadine kinetics in healthy elderly men: implications for influenza prevention. Clin Pharmacol Ther 1985; 37 (2): 137-44
26. Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother 1986; 29 (2): 339-41
27. Zlydnikov DM, Kubar OI, Kovaleva TP, et al. Study of rimantadine in the USSR: a review of the literature. Rev Infect Dis 1981; 3 (3): 408-21
28. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80 (2): 275-82
29. Thompson J, Fleet W, Lawrence E, et al. A comparison of acetaminophen and rimantadine in the treatment of influenza A infection in children. J Med Virol 1987; 21 (3): 249-55
30. Doyle WJ, Skoner DP, Alper CM. et al. Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis 1998; 177 (5): 1260-5
31. Munoz FM, Campbell JR, Atmar RL, et al. Influenza A virus outbreak in a neonatal intensive care unit. Pediatr Infect Dis J 1999; 18(9): 811-5
32. Shiraishi K, Mitamura K, Sakai-Tagawa Y, et al. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003; 188 (1): 57-61
33. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26 (6): 1418-24
34. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176: 119-30
35. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991; 134 (9): 988-97
36. Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321 (25): 1696-702
37. Keyser LA, Karl M, Nafziger AN, et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000; 160 (10): 1485-8
38. Stange KC, Little DW, Blatnik B. Adverse reactions to amantadine prophylaxis of influenza in a retirement home. J Am Geriatr Soc 1991; 39 (7): 700-5
39. Englund JA. Antiviral therapy of influenza. Semin Pediatr Infect Dis 2002; 13 (2): 120-8
40. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections: GG167 Influenza Study Group. N Engl J Med 1997; 337 (13): 874-80
41. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999; 44 Suppl. B: 23-9
42. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections: the MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998; 352 (9144): 1877-81
43. Mäkelä MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000; 40 (1): 42-8
44. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000; 19 (5): 410-7
45. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161 (2): 212-7
46. Murphy KR, Einindson A, Pauksens K, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin Drug Invest 2000; 20 (5): 337-49
47. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000 Mar 4; 355 (9206): 827-35
48. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282 (13): 1240-6
49. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283 (8): 1016-24
50. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355 (9218): 1845-50
51. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51 (1): 123-9
52. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20 (2): 127-33
53. Fleming DM. The management of influenza in people of working age. Occup Med (Lond) 2002; 52 (5): 259-63
54. Lee PY, Matchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002 Aug 20; 137 (4): 225-31
55. Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis 2001; 33 (11): 1879-85
56. O'Brien BJ, Goeree R, Blackhouse G, et al. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value Health 2003; 6(2): 116-25
57. Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med 2002; 113 (4): 300-7
58. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003; 139 (5 Pt 1): 321-9
59. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J 2003; 22 (2): 164-77
60. Mauskopf JA, Gates SC, Griffin AD, et al. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics 2000; 17 (6): 611-20
61. Australian national health survey. Canberra: Australian Bureau of Statistics, 1995 [online]. Available from URL: http:// www.abs.gov.au/ausstats/ abs@nsf/9cfdfe271b7930bbca2568 b5007b8618/cd73ace1b3fbaa92ca25688900209ede!Open Document [Accessed 2003 Oct 10]
62. Wutzler PKK, Lode H, Ruf B, et al. Empfehlungen der Konsensuskonferenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) und der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten e.V. (DVV). Chemother J 2003; 12: 1-3
63. Uhnoo I, Linde A, Pauksens K, et al. Treatment and prevention of influenza: Swedish recommendations. Scand J Infect Dis 2003; 35(1): 3-11
64. Brady B. Economic evaluation of zanamivir for the treatment of influenza. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 2001. Technology report no. 13 [online]. Available from URL: http:// www.ccohta.ca/entry_e.html [Accessed 2004 Aug 6]
65. Husereau DR. An assessment of oseltamivir for the treatment of suspected influenza. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 2002. Technology overview no. 7 [online]. Available from URL: http://www.ccohta.ca/entry_e.html [Accessed 2003 Oct 10]
66. American Lung Association. Guidelines for the prevention and treatment of influenza and the common cold [online]. Available from URL: http://www.lungusa.org/site/pp.asp?c= dvLUK9O0E&b=35426#treated [Accessed 2003 Oct 10]